Polaryx Therapeutics, Inc. (PLYX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PLYX SEC filings page.
This page shows Polaryx Therapeutics, Inc. (PLYX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
R&D-led expansion is being funded externally as operating cash generation deteriorates.
R&D spending rose from$2.8M in FY2024 to$6.3M in FY2025, marking a sharp shift toward development investment. Operating cash flow was-$3.9M in FY2025, so that expansion was not funded by operating receipts and instead increased reliance on financing.
The balance sheet remained lightly debt-funded: total liabilities were
Financing cash flow of
Financial Health Signals
Polaryx Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Polaryx Therapeutics, Inc. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Polaryx Therapeutics, Inc. reported a net loss of $9.0M while operations used $3.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Polaryx Therapeutics, Inc. reported -$1.4M in net income in Q2 2026. This represents a decrease of 36.9% from the same quarter a year earlier. Against the prior quarter it is up 45.8%.
Polaryx Therapeutics, Inc. earned -$0.03 per diluted share (EPS) in Q2 2026. This represents a decrease of 50.0% from the same quarter a year earlier. Against the prior quarter it is up 40.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Polaryx Therapeutics, Inc. held $11.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Polaryx Therapeutics, Inc.'s ROE was -12.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 18.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 89.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Polaryx Therapeutics, Inc. invested $719K in research and development in Q2 2026. This represents an increase of 51.1% from the same quarter a year earlier. Against the prior quarter it is up 5.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
PLYX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|
| R&D Expenses | $719K+51.1% | $679K-85.6% | N/A | $476K | $4.7M | N/A |
| SG&A Expenses | $661K+62.0% | $1.3M+280.7% | N/A | $408K | $336K | N/A |
| Operating Income | -$1.4M-56.1% | -$2.0M+61.2% | N/A | -$884K | -$5.1M | N/A |
| Net Income | -$1.4M-36.9% | -$2.5M+49.6% | N/A | -$1.0M | -$5.1M | N/A |
| EPS (Basic) | -$0.03-50.0% | -$0.05+54.5% | N/A | -$0.02 | -$0.11 | N/A |
| EPS (Diluted) | -$0.03-50.0% | -$0.05+54.5% | N/A | -$0.02 | -$0.11 | N/A |
| Diluted Shares (Avg) | 48M+8.1% | 47M+6.5% | N/A | 45M | 44M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
PLYX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|
| Total Assets | $11.8M | $3.5M | $5.2M+3.4% | N/A | N/A | $5.0M |
| Current Assets | $11.8M | $3.5M | $5.2M+3.4% | N/A | N/A | $5.0M |
| Cash & Equivalents | $11.5M | $3.1M | $5.1M+11.3% | N/A | N/A | $4.6M |
| Short-Term Investments | $0 | $0 | $0 | N/A | N/A | $0 |
| Long-Term Investments | $0 | $0 | $0 | N/A | N/A | $0 |
| Total Liabilities | $873K | $1.0M | $605K+109.3% | N/A | N/A | $289K |
| Current Liabilities | $873K | $1.0M | $605K+109.3% | N/A | N/A | $289K |
| Non-Current Liabilities | $0 | $0 | $0 | N/A | N/A | $0 |
| Total Equity | $10.9M+237.0% | $2.5M-41.5% | $4.6M-3.1% | $3.2M | $4.3M | $4.7M |
| Retained Earnings | -$103.6M | -$102.2M | -$99.6M-9.9% | N/A | N/A | -$90.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PLYX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
PLYX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Where Polaryx Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Polaryx Therapeutics, Inc. profitable?
No, Polaryx Therapeutics, Inc. (PLYX) reported a net income of -$9.0M in fiscal year 2025.
What is Polaryx Therapeutics, Inc.'s return on equity (ROE)?
Polaryx Therapeutics, Inc. (PLYX) has a return on equity of -196.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Polaryx Therapeutics, Inc.'s operating cash flow?
Polaryx Therapeutics, Inc. (PLYX) recorded an outflow of $3.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Polaryx Therapeutics, Inc.'s total assets?
Polaryx Therapeutics, Inc. (PLYX) had $5.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Polaryx Therapeutics, Inc. spend on research and development?
Polaryx Therapeutics, Inc. (PLYX) invested $6.3M in research and development during fiscal year 2025.
What is Polaryx Therapeutics, Inc.'s current ratio?
Polaryx Therapeutics, Inc. (PLYX) had a current ratio of 8.55 as of fiscal year 2025, which is generally considered healthy.
What is Polaryx Therapeutics, Inc.'s debt-to-equity ratio?
Polaryx Therapeutics, Inc. (PLYX) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Polaryx Therapeutics, Inc.'s return on assets (ROA)?
Polaryx Therapeutics, Inc. (PLYX) had a return on assets of -173.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Polaryx Therapeutics, Inc.'s P/E ratio?
Polaryx Therapeutics, Inc. (PLYX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $101.9M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Polaryx Therapeutics, Inc.'s price-to-sales ratio?
Polaryx Therapeutics, Inc. (PLYX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $101.9M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Polaryx Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Polaryx Therapeutics, Inc. (PLYX) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.9M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Polaryx Therapeutics, Inc.'s Piotroski F-Score?
Polaryx Therapeutics, Inc. (PLYX) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Polaryx Therapeutics, Inc.'s earnings high quality?
Polaryx Therapeutics, Inc. (PLYX) reported a net loss of $9.0M while operations used $3.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.